The share of British households with at least one GLP-1 user reached 8.5% in August, according to Worldpanel by Numerator. That is a jump from the 6.3% recorded in February and almost four times the level in 2024

Some 2.6 million adults are now taking the drugs. GLP-1 users are found in as many households as vegetarians and pescatarians combined, or as many as buy Corona beer or Kellogg’s Rice Krispies, Worldpanel highlighted.

Weight-loss drugs have cut annual grocery spend in Britain by more than £1bn, up from £780m in February. Worldpanel bases the figure on the drop in grocery spend among households in their first year using GLP-1s, compared with households that don’t use them. The total is equivalent to £389 less per user household, slightly lower than the £418 in the previous study, but more than offset by the rise in users.

Findings are based on responses from 9,629 households in the fourth study of this type, starting in March 2024. Worldpanel identified pills and a rise in male users as two drivers behind the growth of GLP-1s.


Pills already account for 11.2% of users, even though the medicines and healthcare products Regulatory Agency (MHRA) only approved the first GLP-1 tablet for weight loss, Novo Nordisk’s Wegovy, in June. It was followed by Eli Lilly’s Foundayo in August.

Worldpanel senior consultant Nishita Pattni said some users had stopped taking the drugs because they did not want to inject themselves.

“It’s quite scary, you have to stick to a schedule, whereas the pill format makes that so much easier and it removes one key access barrier,” she said.

Men now make up 32% of all users, up from 23% in February. That’s nearly twice as many male users, rising from 440,000 to 830,000. Pattni said weight loss has overtaken type 2 diabetes as the main reason for taking the drugs, among men as well as women.

Worldpanel estimates GLP-1 usage will pass 10% of British households in 2027. 

Pattni said the forecast draws on what has happened in other markets such as the US, where almost one in five households has a GLP-1 user and adoption jumped when the pill launched.

Less alcohol, more hot chocolate

Products associated with impulse and indulgence purchases are taking the biggest hit. Spend on alcohol and crisps among users has fallen 15% more than in non-user households.

In contrast, portion-controlled options are gaining ground. Frozen ready meals have seen a 30% uplift in volume, while unexpected winners are hot chocolate and malt drinks, up 22% in spend and 16% in volume.

Pattni said the jump in hot chocolate could be linked to users looking for small indulgences, similar to the so-called lipstick effect.

“Our users are telling us that they do have less disposable income since being on GLP-1 drugs. Especially if you’re not prescribed it, it can be a financial strain,” she said. “Hot chocolate feels like a sweet spot, quite literally.”

Half of users say they no longer experience food cravings, Pattni said, and the drugs make them more sensitive to stimulants, with users claiming to cut back on energy drinks.

Some of the displaced money is also going beyond the grocery aisle. GLP-1 users spent £78m more than expected on health and beauty products in the first year after adoption, and 30% said they had spent more on clothing and footwear.

How retailers can respond

Worldpanel head of public sector and nutrition Chantel Kennaugh said too often the GLP-1 impact was framed as a story about sales decline, but from a grocery perspective she saw a new audience more mindful about what and how they eat.

“The key for retailers is how to support them, without isolating them,” Kennaugh said. “This might be as simple as producing clear labels that highlight nutrients like high protein or ensuring ranges are available in smaller portion sizes.”

Pattni pointed to M&S’ nutrient-dense range and Boots’ in-store signposting as examples of retailers adapting to GLP-1 users.

“These groups are not a niche trend,” she said. “They’re here, they’re growing, they’re here to stay.”